Compare MFA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | ABUS |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 839.5M |
| IPO Year | 1998 | 2008 |
| Metric | MFA | ABUS |
|---|---|---|
| Price | $8.78 | $5.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $11.05 | $5.00 |
| AVG Volume (30 Days) | 1.4M | ★ 3.9M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ 58.54 | 55.26 |
| EPS | 0.23 | ★ 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | $239.71 |
| P/E Ratio | $37.74 | ★ $6.06 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $8.63 | $3.50 |
| 52 Week High | $10.57 | $5.45 |
| Indicator | MFA | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 34.09 | 62.69 |
| Support Level | N/A | $4.12 |
| Resistance Level | $9.68 | $5.42 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 12.80 | 64.44 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.